504
Views
8
CrossRef citations to date
0
Altmetric
Research Article

Investigation on the binding mode of benzothiophene analogues as potent factor IXa (FIXa) inhibitors in thrombosis by CoMFA, docking and molecular dynamic studies

, , &
Pages 792-804 | Received 14 Oct 2010, Accepted 11 Jan 2011, Published online: 07 Mar 2011

References

  • Batt DG, Qiao JX, Modi DP, Houghton GC, Pierson DA, Rossi KA et al. 5-Amidinoindoles as dual inhibitors of coagulation factors IXa and Xa. Bioorg Med Chem Lett 2004;14:5269–5273.
  • Murcia M, Ortiz AR. Virtual screening with flexible docking and COMBINE-based models. Application to a series of factor Xa inhibitors. J Med Chem 2004;47:805–820.
  • Fontaine F, Pastor M, Zamora I, Sanz F. Anchor-GRIND: filling the gap between standard 3D QSAR and the GRid-INdependent descriptors. J Med Chem 2005;48:2687–2694.
  • Srámek A, Kriek M, Rosendaal FR. Decreased mortality of ischaemic heart disease among carriers of haemophilia. Lancet 2003;362:351–354.
  • Feuerstein G, Stern D. The coagulation factor lottery: is 9 the winning number? An essay on future oral anticoagulants. Drug Discov Today Ther Strateg 2005;2:279–283.
  • Srámek A, Kriek M, Rosendaal FR. Decreased mortality of ischaemic heart disease among carriers of haemophilia. Lancet 2003;362:351–354.
  • Spanier TB, Chen JM, Oz MC, Edwards NM, Kisiel W, Stern DM et al. Selective anticoagulation with active site-blocked factor IXA suggests separate roles for intrinsic and extrinsic coagulation pathways in cardiopulmonary bypass. J Thorac Cardiovasc Surg 1998;116:860–869.
  • Vijaykumar D, Sprengeler PA, Shaghafi M, Spencer JR, Katz BA, Yu C et al. Discovery of novel hydroxy pyrazole based factor IXa inhibitor. Bioorg Med Chem Lett 2006;16:2796–2799.
  • Smallheer JM, Alexander RS, Wang J, Wang S, Nakajima S, Rossi KA et al. SAR and factor IXa crystal structure of a dual inhibitor of factors IXa and Xa. Bioorg Med Chem Lett 2004;14:5263–5267.
  • Qiao JX, Cheng X, Modi DP, Rossi KA, Luettgen JM, Knabb RM et al. 5-Amidinobenzo[b]thiophenes as dual inhibitors of factors IXa and Xa. Bioorg Med Chem Lett 2005;15:29–35.
  • Wang S, Beck R, Blench T, Burd A, Buxton S, Malic M et al. Studies of benzothiophene template as potent factor IXa (FIXa) inhibitors in thrombosis. J Med Chem 2010;53:1465–1472.
  • Wang S, Beck R, Burd A, Blench T, Marlin F, Ayele T et al. Structure based drug design: development of potent and selective factor IXa (FIXa) inhibitors. J Med Chem 2010;53:1473–1482.
  • Richard D, David E, Jeffrey D. Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J Am Chem Soc 1988;110:5959–5967.
  • Murthy VS, Kulkarni VM. 3D-QSAR CoMFA and CoMSIA on protein tyrosine phosphatase 1B inhibitors. Bioorg Med Chem 2002;10:2267–2282.
  • Nayyar A, Malde A, Jain R, Coutinho E. 3D-QSAR study of ring-substituted quinoline class of anti-tuberculosis agents. Bioorg Med Chem 2006;14:847–856.
  • Wang X, Yang W, Xu X, Zhang H, Li Y, Wang Y. Studies of benzothiadiazine derivatives as hepatitis C virus NS5B polymerase inhibitors using 3D-QSAR, molecular docking and molecular dynamics. Curr Med Chem 2010;17:2788–2803.
  • Ryu CK, Lee Y, Park SG, You HJ, Lee RY, Lee SY et al. 3D-QSAR studies of heterocyclic quinones with inhibitory activity on vascular smooth muscle cell proliferation using pharmacophore-based alignment. Bioorg Med Chem 2008;16:9772–9779.
  • Pandey G, Saxena AK. 3D QSAR studies on protein tyrosine phosphatase 1B inhibitors: comparison of the quality and predictivity among 3D QSAR models obtained from different conformer-based alignments. J Chem Inf Model 2006;46:2579–2590.
  • Chaudhaery SS, Roy KK, Saxena AK. Consensus superiority of the pharmacophore-based alignment, over maximum common substructure (MCS): 3D-QSAR studies on carbamates as acetylcholinesterase inhibitors. J Chem Inf Model 2009;49:1590–1601.
  • Cui M, Huang X, Luo X, Briggs JM, Ji R, Chen K et al. Molecular docking and 3D-QSAR studies on gag peptide analogue inhibitors interacting with human cyclophilin A. J Med Chem 2002;45:5249–5259.
  • Buolamwini JK, Assefa H. CoMFA and CoMSIA 3D QSAR and docking studies on conformationally-restrained cinnamoyl HIV-1 integrase inhibitors: exploration of a binding mode at the active site. J Med Chem 2002;45:841–852.
  • Muegge I, Podlogar B. 3D-quantitative structure activity relationships of biphenyl carboxylic acid MMP-3 inhibitors: exploring automated docking as alignment method. Quant Struct–Act Relat 2001;20:215–222.
  • Jain AN. Surflex-Dock 2.1: robust performance from ligand energetic modeling, ring flexibility, and knowledge-based search. J Comput Aided Mol Des 2007;21:281–306.
  • Golbraikh A, Tropsha A. Beware of q2! J Mol Graph Model 2002;20:269–276.
  • Tropsha A, Gramatica P, Gombar V. The importance of being earnest: validation is the absolute essential for successful application and interpretation of QSPR models. QSAR Comb Sci 2003;22:69–77.
  • Golbraikh A, Shen M, Xiao Z, Xiao YD, Lee KH, Tropsha A. Rational selection of training and test sets for the development of validated QSAR models. J Comput Aided Mol Des 2003;17:241–253.
  • Golbraikh A, Tropsha A. Predictive QSAR modeling based on diversity sampling of experimental datasets for the training and test set selection. J Comput Aided Mol Des 2002;16:357–369.
  • Hao M, Li Y, Wang Y, Zhang S. Prediction of PKCθ inhibitory activity using the Random Forest algorithm. Int J Mol Sci 2010;11:3413–3433.
  • Li Y, Wang Y, Ding J, Wang Y, Chang Y, Zhang S. In silico prediction of androgenic and nonandrogenic compounds using random forest. QSAR Comb Sci 2009;28:396–405.
  • Sun X, Li Y, Liu X, Ding J, Wang Y, Shen H et al. Classification of bioaccumulative and non-bioaccumulative chemicals using statistical learning approaches. Mol Divers 2008;12:157–169.
  • Zhu YQ, Lei M, Lu AJ, Zhao X, Yin XJ, Gao QZ. 3D-QSAR studies of boron-containing dipeptides as proteasome inhibitors with CoMFA and CoMSIA methods. Eur J Med Chem 2009;44:1486–1499.
  • Song M, Breneman CM, Sukumar N. Three-dimensional quantitative structure–activity relationship analyses of piperidine-based CCR5 receptor antagonists. Bioorg Med Chem 2004;12:489–499.
  • Leonard J, Roy K. On selection of training and test sets for the development of predictive QSAR models. QSAR Comb Sci 2006;25:235–251.
  • Gasteiger J, Marsili M. Iterative partial equalization of orbital electronegativity-a rapid access to atomic charges. Tetrahedron 1980;36:3219–3228.
  • Clark M, Cramer III R, Van Opdenbosch N. Validation of the general purpose Tripos 5.2 force field. J Comput Chem 1989;10:982–1012.
  • Jain AN. Surflex: fully automatic flexible molecular docking using a molecular similarity-based search engine. J Med Chem 2003;46:499–511.
  • Böhm M, St rzebecher J, Klebe G. Three-dimensional quantitative structure–activity relationship analyses using comparative molecular field analysis and comparative molecular similarity indices analysis to elucidate selectivity differences of inhibitors binding to trypsin, thrombin, and factor Xa. J Med Chem 1999;42:458–477.
  • Wold S, Ruhe A, Wold H, Dunn III W. The collinearity problem in linear regression. The partial least squares (PLS) approach to generalized inverses. SIAM J Sci Stat Comput 1984;5:735–743.
  • Cramer RD, Bunce JD, Patterson DE, Frank IE. Cross-validation, bootstrapping, and partial least-squares compared with multiple-regression in conventional QSAR studies. Quant Struct–Act Relat 1988;7:18–25.
  • Wold S. Cross-validatory estimation of the number of components in factor and principal components models. Technometrics 1978;20:397–405.
  • Case DA, Darden TA, Cheatham ITE, Simmerling CL, Wang J, Duke RE, Luo R, Merz KM, Pearlman DA, Crowley M, Walker RC, Zhang W, Wang B, Hayik S, Roitberg A, Seabra G, Wong KF, Paesani F, Wu X, Brozell S, Tsui V, Gohlke H, Yang L, Tan C, Mongan J, Hornak V, Cui G, Beroza P, Mathews DH, Schafimeister C, Ross WS, Kollman PA. AMBER9, University of California, San Francisco, 2006.
  • Dewar M, Zoebisch E, Healy E, Stewart J. AM1: a new general purpose quantum mechanical molecular model. J Am Chem Soc 1985;107:3902–3909.
  • Jakalian A, Bush B, Jack D, Bayly C. Fast, efficient generation of high-quality atomic charges. AM1-BCC model: I. Method. J Comput Chem 2000;21:132–146.
  • Wang J, Morin P, Wang W, Kollman PA. Use of MM-PBSA in reproducing the binding free energies to HIV-1 RT of TIBO derivatives and predicting the binding mode to HIV-1 RT of efavirenz by docking and MM-PBSA. J Am Chem Soc 2001;123:5221–5230.
  • Jorgensen W, Chandrasekhar J, Madura J, Impey R, Klein M. Comparison of simple potential functions for simulating liquid water. J Chem Phys 1983;79:926–935.
  • Ryckaert J-P, Ciccotti G, Berendsen HJC. Numerical integration of the cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes. J Comput Phys 1977;23:327–341.
  • Essmann U, Perera L, Berkowitz M, Darden T, Lee H, Pedersen L. A smooth particle mesh Ewald method. J Chem Phys 1995;103:8577–8593.
  • Berendsen H, Postma J, Van Gunsteren W, DiNola A, Haak J. Molecular dynamics with coupling to an external bath. J Chem Phys 1984;81:3684–3690.
  • Hopfner KP, Lang A, Karcher A, Sichler K, Kopetzki E, Brandstetter H et al. Coagulation factor IXa: the relaxed conformation of Tyr99 blocks substrate binding. Structure 1999;7:989–996.
  • Brandstetter H, Bauer M, Huber R, Lollar P, Bode W. X-ray structure of clotting factor IXa: active site and module structure related to Xase activity and hemophilia B. Proc Natl Acad Sci USA 1995;92:9796–9800.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.